Oligonol Clinical Studies
Mamoru O, et al. The supplementation therapy of canine dermatology in my hospital. Clinical Note Regarding Small-sized Animal. 2008:27(6):1-7.
Topic: Does treatment with Oligonol® contribute to improved outcomes in dogs undergoing treatment for dermatological conditions?
Background: Oligonol® has previously been shown to improve skin condition in humans. The following case studies describe dogs presenting dermatological conditions. Oligonol® was utilized in the treatment of each of these patients.
An 11-year old, female, Shiba Inu presenting with sever rash surrounding eyes, ears, and mouth was the subject of this case study. The patient also presented with erythema, scaling in the areas with rashes, as well as pigmentation and lichenization of abdominal and inguninal regions. Initial treatment regime consisted of 1mg/kg BW BDI Trandospirone citrate, and 2mg/kg BW BDI Oxaromide. In instances of severe itching 15mg/kg BW BDI Cephalexin (2 doses/week) and 0.5mg/kg BW. Prednisolone were also administered. Additionally, dietary therapy was administered as KS joint low molecular weight proteins. There was no improvement in symptoms following initiation of this treatment regime. Following this observation, Oligonol® and glucosylceramide were incorporated into the treatment regime. After 15 weeks of treatment with Oligonol® and glucosylceramide, improved quality of symptoms was observed.
An 8 year-old, female, mixed breed dog presenting with itching and erythema in regions surrounding the ears, mouth, and between limbs was the subject of this case study. The patient also presented with scaling, pigmentation, and lichenization in the front and rear axilla. The primary diagnosis of allergic dermatitis and secondary malasseziosis was made. Initial treatment
consisted of 1mg/kg BW Prednisolone, 15mg/kg BW BID Cephalexin, and 10mg/kg BW SID Ketoconazole, but only limited improvement was observed. Antimycotic treatment was changed from Ketoconazole to 10mg/kg BW SID Itrizole and dietary therapy was initiated, which included skin support. Finally, treatment with Oligonol® and glucosylceramide were started. Following 25 weeks of treatment, the patient’s symptoms showed improvement presenting decreased itching, erythema, scaling, lichenization, and pigmentation.
Conclusion: In the above case studies, symptoms of patients improved in conjunction with inclusion of Oligonol® into the therapeutic regimen.